Pfizer Inc PFE

$27.80 -0.32 (-1.14%)

Valuation

Market cap
158,450,928,000
Revenue TTM
$62,579,000,000
Net income TTM
$7,771,000,000
PE ratio
9.22
Forward PE
9.45
Profit margin
12.42%
Debt to equity
0.74

Trading

Volume
35,007,800
Avg volume
36,037,438
Day's range
$27.44 – $28.16
Shares out
5,699,674,000
Stochastic %K
24%
Beta
0.32
Analysts
Sell
Price target
$28.95

Price

Company profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under...

Show more

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
212 733 2323
Website
https://www.pfizer.com
Address
66 Hudson Boulevard East, New York, United States

Latest news

Stocktwits

moneybag888 Oct 5, 7:14 AM 0 replies
Diehard777 Oct 5, 6:58 AM
$PFE BIG BREAKING: Plague outbreak expands, Russia BSL-3 lab accident - FIVE hospitals now quarantined🚨☣️ The plague outbreak in Siberia, Russia has expanded w/5 hospitals now under QUARANTINE: Irkutsk Hospitals No. 1, No.3, No.10, Ivano-Matreninskaya Children's Hospital, and an unnamed maternity hospital (Lyudi Baikala news, Moscow Times). Who is going make antibiotics for this outbreak ? Think 💥💥💥
0 replies
DudeNamedBenOG Oct 5, 6:20 AM
$PFE if this pneumatic plague this goes anywhere Pfizer Going to get $$$FUNDING to manufacture streptomycin antibiotics for plague. They already have manufactured it before. They are a shoe in for the money.
0 replies
MajorFutesARippin Oct 5, 5:46 AM
$PFE has a plague vaccine, right? Right?
1 replies
Unhappytrader28 Oct 5, 4:09 AM
$MRNA $PFE let open a little something here tomorrow just incase.
0 replies
FactorPort Oct 5, 3:37 AM
$PFE this can retest the 26.8-27 level, esp with XLV relative performance is weakening lately. I read it as a healthy consolidation, unless it breaks 27 level with volume.
0 replies
biolover Oct 4, 7:12 PM
$VKTX Obesity drug performance Software modeling based on published clinical data , Pk and exposure has proven very accurate. This is @GilaMonstrum predicting $LLY TZP performance if rapidly escalated like $VKTX trial. Also included retatrutide if escalated 2 mg q 2 Wks ( starting at 2 mg dose which is not trivial ). But also look at real life trials performance .. focus on first 4 wks. Vk did 1.25 mg for a wk , 2.5 mg another wk and then 5 mg for 2 Wks. Vs TZP 2.5 mg for 4 Wksin surmount 5. Difference in AUC is minimal but look at difference in wt loss.. 3% with TZP from phase 3 figure. Vs almost 5% with VK2735. What is missing still female ratio .. although in Lilly TZP vs Sema trial were 65% females so I doubt gender to account for that sizable difference in 4 wks. We need @GilaMonstrum show recent projection of vanquish vs Triumph 1 ? Bourla $PFE started doing some modeling but little late .: hard to model GLP1 plus amylin due to tolerability issues.
0 replies
taxplanr Oct 4, 10:57 AM
Israel covered up hundreds of COVID vaccine deaths as well as the CDC $MRNA $PFE $BNTX https://www.instagram.com/reel/DdwQNxpRRRQ/?stkn=cnpuaDBnYWQ4bGl1
5 replies